1. Membrane Transporter/Ion Channel
    Neuronal Signaling
  2. nAChR
  3. PHA 568487

PHA 568487 

Cat. No.: HY-107666
Handling Instructions

PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR).PHA 568487 reduces neuroinflammation and oxidative stress. PHA-568487 has rapid brain penetration.

For research use only. We do not sell to patients.

PHA 568487 Chemical Structure

PHA 568487 Chemical Structure

CAS No. : 527680-57-5

Size Price Stock
5 mg USD 100 Ask For Quote & Lead Time
10 mg USD 160 Ask For Quote & Lead Time
50 mg USD 720 Ask For Quote & Lead Time
100 mg USD 1150 Ask For Quote & Lead Time

* Please select Quantity before adding items.

Other In-stock Forms of PHA 568487:

Other Forms of PHA 568487:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR)[1][2].PHA 568487 reduces neuroinflammation and oxidative stress[2]. PHA-568487 has rapid brain penetration[3].

In Vitro

PHA 568487 increases anti-oxidant gene expression and decreases oxidative stress and phosphorylation of NF-κb p65. Methyllycaconitine (MLA) has the opposite effects[2].
PHA increases anti-oxidant genes and NADPH oxidase expression associated with decreased phosphorylation of NF-kB p65 in microglia/macrophages[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PHA 568487 attenuates neuronal injury and behavioral dysfunction in mice with ischemic stroke only and ischemic stroke plus tibia fracture[2].
PHA 568487 (1.25 mg/kg; i.p.; treated daily)-treated ischemic rats shows a significant reduction of the cerebral infarct volumes and an improvement of the neurologic outcome[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J male mice (10-12 weeks old)[2]
Dosage: PHA 568487 (PHA; 0.4 and 0.8 mg/kg); Methyllycaconitine (MLA; 4 and 6 mg/kg)
Administration: Injected intraperitoneally once on day 1, or twice on days 1 and 2, after pMCAO
Result: Injection of PHA (0.8 mg/kg) and MLA (6 mg/kg) on days 1 and 2 after pMCAO yielded the best effect on infarct volume and behavior tests.
Animal Model: Adult male Sprague-Dawley rats (297 6±8.3 g)[4]
Dosage: 1.25 mg/kg
Administration: I.p.;0.1 mL; treated daily
Result: Showed a significant reduction of the cerebral infarct volumes and an improvement of the neurologic outcome.
Molecular Weight

404.41

Formula

C20H24N2O7

CAS No.
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PHA 568487
Cat. No.:
HY-107666
Quantity:
MCE Japan Authorized Agent: